- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pearson Outlines the Goals of ICER's Drug Assessment Program
The Institute for Clinical and Economic Review (ICER) created a new drug assessment program with the goal of changing how drugs are priced and evaluated, according to Steven Pearson, MD, MSc, FRCP, founder and president of ICER.
The Institute for Clinical and Economic Review (ICER) created a new drug assessment program with the goal of changing how drugs are priced and evaluated, according to Steven Pearson, MD, MSc, FRCP, founder and president of ICER.
Transcript (modified)
What are the goals of the ICER’s new drug assessment program?
From our perspective, the current landscape for how drugs are priced and evaluated, especially at or near the time of FDA approval, has really been broken. In some ways it’s been a black box, but what we do know is that there has not been any consistent way for the discussions about effectiveness and value to be woven into the way that drugs are covered and priced at the beginning.
There’s still a lot to do, also, with drugs that have been on the market for a long time, when the evidence of their effectiveness or their price changes rapidly. But our new program is meant to “ramp up” the focus, primarily in the short term, on emerging, significant drugs at or near the time of their approval. And our goal is to provide reports that can be used by insurers, by doctors’ groups, by policy makers, and by patients, to try to get a much clearer view of the comparative effectiveness and value of these drugs.
With that information we now include what we call a value-based price benchmark. And that, too, is meant to send a signal that, if we wish to do a better job of pricing drugs according to the added benefits that they bring to patients, we want to provide a marker to kind of trigger the right discussions, negotiations, and policies that will focus on value.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
